Realistically, how much hair will 1 mg put back on my head?
Do not mix the 1 mg ledger with the 5 mg ledger
Claim on the board: one vanity hair pill accidentally shrinks prostates. Label the record instead as two randomised programs that never shared a dose or a primary endpoint.
Finasteride blocks type 2 5-alpha-reductase and drops circulating DHT by about 65 percent. DHT enlarges prostate tissue and miniaturises balding follicles, so cutting it hits both organs. That is the whole mechanism. Everything below is arithmetic on that fact. Hair evidence uses 1 mg daily in men 18 to 41 with early thinning. Prostate evidence uses 5 mg daily in older men with enlarged glands. Swapping those numbers is the commonest error in 'reviews' of this drug.
Score each line on its own endpoints. The 1 mg line really slows visible loss and modestly thickens some crowns. The 5 mg line really cuts acute retention and prostate surgery over years. Effect sizes are steady, not cinematic. The tablet only works while you swallow it. How both uses sprang from one genetic observation is the 5-alpha history file. This page stays with what was measured.
Kaufman's circle: 107 hairs, then 138, then 277
The pivotal 1 mg program, published by Kaufman and colleagues in 1998, randomised 1,553 men with vertex-pattern loss to finasteride 1 mg or placebo for a year, then kept most of them in blinded extensions. Endpoints were blunt on purpose: hair counts in a 1-inch (5.1 cm2) circle, patient questionnaires, investigator grades, and a blinded photo panel. At 12 months the treated group sat 107 hairs above placebo in that circle. At two years the gap was 138. At five years, because placebo kept sliding, the gap reached 277 hairs.
Read those gaps as hold-plus-some, not a hairline reset. At one year, 14 percent of treated men had any further count loss versus 58 percent on placebo. Investigators called 65 percent of 1 mg men improved at 12 months versus 37 percent on placebo. The independent photo panel was harsher: 48 percent improved on drug versus 7 percent on placebo at one year. Crown and mid-scalp moved. Deep bitemporal recession was not the counted zone. A 12-month study in postmenopausal women showed no benefit. File the 1 mg promise as 'keep most of what you have, recover a little at the vertex.' Stop the tablet and the count advantage reverses within a year.
PLESS: retention and surgery, not a flow slogan
On the 5 mg line, symptom scores matter - but the endpoints men actually fear are a catheter for acute retention and an operation.
The Proscar Long-Term Efficacy and Safety Study followed 3,040 men with moderate to severe BPH symptoms for four years. Finasteride 5 mg cut the risk of acute urinary retention by 57 percent and the need for BPH-related surgery by 55 percent versus placebo. Median prostate volume fell about 18 percent. Men with genuinely large glands gained more, because there was more DHT-driven tissue to lose. Men with small glands and night walking from another cause often gained little. That size dependence is the clearest trial lesson on this line: 5 mg is therapy for enlargement, not for every man who wakes to urinate.
Flow and bother scores moved, but they moved slowly. Counsel that way. A 5 mg tablet is not an alpha-blocker. It will not relax smooth muscle in days. It shrinks tissue over months. If a man needs a fast stream change, another class does that job. If he needs fewer crises over years, this is the ledger that supports the claim.
MTOPS paired a shrinker with a relaxer
The Medical Therapy of Prostatic Symptoms trial enrolled 3,047 men and ran four to six years. It compared placebo, finasteride 5 mg, doxazosin (an alpha-blocker), and the pair. Combination reduced overall clinical progression more than either drug alone. Different clocks, one program: doxazosin relaxes prostatic smooth muscle within days; finasteride shrinks volume over months. That is why urologists still stack them in larger glands instead of pretending one tablet covers both tempos.
MTOPS also left a safety footnote the label still carries: four cases of male breast cancer in men who received finasteride, none in men who did not, in that study. PLESS had the opposite split - two cases on placebo, none on drug. PCPT had one case on each arm. The relationship between long-term finasteride and male breast neoplasia is listed as unknown. Report new breast lumps, pain, or nipple discharge. Do not turn a rare, unsettled signal into a slogan. Dosing that follows from these data sits in the 1 mg cost and honesty guide.
PCPT cut cancers and left a Gleason asterisk
The Prostate Cancer Prevention Trial randomised 18,882 men aged 55 or older with a normal rectal exam and PSA at or below 3.0 ng/mL to finasteride 5 mg or placebo for seven years, then biopsied. Overall prostate-cancer detection fell from 24.4 percent on placebo to 18.4 percent on drug - a 24.8 percent relative reduction. That is a real prevention signal for an inexpensive, familiar tablet. It is also not an approved indication. The US label says finasteride is not approved to prevent prostate cancer.
Then the asterisk that dominated headlines. Gleason 8 to 10 cancers were more common on finasteride (1.8 percent) than on placebo (1.1 percent). High-grade (Gleason 7 to 10) fractions ran 6.4 percent versus 5.1 percent. Dutasteride later showed a similar high-grade pattern. Years of argument followed: the drug shrinks glands and changes PSA, which can make biopsies and screening more sensitive to aggressive disease, so part of the excess may be detection, not causation. The question is not closed. I file it as written: real drop in total cancers, debated high-grade signal, and a reason nobody should swallow 5 mg as a cancer-prevention plan.
The half-cut PSA that rewrites a blood test
Even a man who never thinks about cancer needs this line: the tablet reshapes a marker clinicians use every week.
Prostate-specific antigen falls about 50 percent after six to twelve months on finasteride, because the gland makes less of it once volume drops. The shift is expected. It is dangerous only if nobody adjusts. A 'normal' number can hide a trend that would have triggered work-up on an untreated scale. The correction is automatic once you know it: roughly double the reported PSA before comparing to untreated ranges, and watch direction more than any single draw.
A rising PSA on therapy is the red flag, because the drug should be holding production down. Tell whoever orders the test. A cheap 1 mg hair tablet does this too, not only the 5 mg gland tablet. More on that trap - plus pregnancy handling and sexual-signal percents - sits in the 1 mg cost and honesty guide.
Score both lines, then stop shopping for a miracle
Stack the uses by data strength and by the kind of benefit you should expect. The pattern is obvious once the ledgers stay apart.
| Use | Dose | Best evidence | Verdict |
|---|---|---|---|
| Male pattern hair loss | 1 mg (Propecia) | Kaufman RCTs, counts + photos to 5 y | Approved; holds hair, some vertex gain |
| Benign prostatic hyperplasia | 5 mg (Proscar) | PLESS: AUR -57%, surgery -55% | Approved; best for larger glands |
| Reducing BPH progression | 5 mg + alpha-blocker | MTOPS combination | Pair beats either alone |
| Prostate cancer prevention | 5 mg | PCPT: 24.8% fewer cancers | Not approved; Gleason 8-10 row |
| Female pattern hair loss | 1 mg studied | 137 postmenopausal women, 12 mo | No benefit shown; pregnancy ban |
The table pairs each use with its best supporting evidence and a plain verdict. Approved indications are solid. Cancer prevention is real and hedged. None of the effect sizes are blockbuster-sized. That is the right tone for a drug this widely prescribed, including the generic 1 mg strips sold as hair reviews.
Finasteride, dutasteride, minoxidil are not twins
| Finasteride | Dutasteride | Minoxidil | |
|---|---|---|---|
| Mechanism | Type 2 5-AR block | Type 1 and 2 block | Not hormonal |
| DHT lowering | ~65% | ~90%+ | None |
| Main measured use | Hair 1 mg; BPH 5 mg | BPH; hair off-label | Hair, topical or low oral |
| Clock | Months for visible change | Long half-life; slow washout | Shed first, then hold |
| Honesty line | Sexual AEs labelled | Same class concerns | No DHT debate; still not a cure |
Dutasteride blocks type 1 and type 2 and suppresses DHT more completely - often over 90 percent versus about 65 to 70 percent for finasteride - with a much longer half-life. Stronger gland effect in some men. Same sexual-signal conversation, sometimes louder. Widely used for BPH. Often used off-label for hair. Minoxidil ignores DHT. It is thought to extend anagen and change local perfusion. It complements a 1 mg tablet rather than replacing it. Early shed on minoxidil is common and is not proof the plan failed.
Clinic read: 1 mg plus topical minoxidil covers two independent steps and is the usual medical backbone for male-pattern loss. Dutasteride is the heavier DHT hammer when 1 mg underperforms and a clinician is willing to use it off-label for hair. None is permanent. All need ongoing use. Sexual-signal honesty belongs in the consult, not in a cart blurb. Core pharmacology of the 1 mg tablet is on the Propecia 1 mg fact line.
Reader mail
Reader questions on this article
Answered by Dr. Priya Anand, MD · Urology & men's health
After the two-ledger file published, readers asked for numbers, not slogans. These are the recurring ones.
Preservation first, regrowth second. Across the five-year 1 mg program, most men stopped visible loss. Investigators called about two-thirds improved at one year; the blinded photo panel was closer to half. Likely outcome: keep most current density and recover a modest amount at the crown, not a rebuilt frontal hairline. Bare scalp often means the unit is gone. No tablet revives a dead follicle. Treat 1 mg as a brake with a possible bonus. Judge after a full year with matched photos, not memory. A sober overview sits at Mayo Clinic.
Does 5 mg shrink every prostate, or only the large ones?
Mostly the large ones - and casual talk skips that. Volume drops roughly a fifth. Symptom relief tracks starting size. Men with truly enlarged glands see clearer flow change and the PLESS-style drop in retention and surgery. Men with small glands and another cause of night walking often see little; an alpha-blocker or another work-up may fit better. That is why urologists estimate size - PSA as a rough proxy or imaging - before defaulting to 5 mg. Prescribing blind is how this line gets a bad reputation it did not earn in the enlarged-gland trials.
PCPT found fewer cancers but more aggressive ones. Which number do I keep?
Keep both, and do not collapse them into a slogan. Overall detection fell by about a quarter. Gleason 8 to 10 ran 1.8 percent on finasteride versus 1.1 percent on placebo. The most plausible post-hoc read is mixed: some true prevention of lower-grade disease, plus a detection effect because a smaller gland and a halved PSA change how we find high-grade tumours. Not fully settled. Finasteride is not prescribed to prevent cancer. I would not take 5 mg for that reason alone, and I would not treat the high-grade row as proof the tablet causes aggressive cancer. File the asterisk. Do not file a panic.
My PSA is low on the tablet. Does that mean I am clear?
Not automatically. This is the trap the drug creates. Finasteride roughly halves PSA within six to twelve months, so a comfortable raw number can be misleading until you double it for comparison. Trend beats any single draw. A rising PSA on therapy is concerning because the drug should suppress it. Low is not synonymous with safe. Upward drift warrants proper evaluation. Tell whoever orders the test that you take finasteride - 1 mg or 5 mg - or the arithmetic never happens. A hair-line reader is not exempt from this rule.
Is dutasteride just a stronger, better finasteride?
Stronger DHT suppression, yes. Automatically better, no. Dutasteride blocks both isoforms and lowers DHT by over 90 percent, with a half-life that lingers for weeks. Fuller blockade helps some men, especially on the prostate line, and many countries use it off-label for hair. Trade-off: the same sexual-signal concerns apply at least as much, and a long half-life means unwanted effects clear slowly. Reasonable next step if 1 mg underperforms and a clinician owns the off-label call. Not the default first tablet for a man who has never tried the labelled 1 mg hair dose.
Can I skip hormones and use only minoxidil?
Yes. Many men do. Minoxidil bypasses DHT. That sidesteps the sexual-signal debate, which some patients strongly prefer. Limitation: the two agents hit different steps, so combined use usually beats either alone on the hair line. Minoxidil monotherapy is legitimate, just weaker for many scalps. Expect an early shed when you start. Unsettling. Normal. Not a reason to quit in month one. If you want the DHT lever as well, that is the 1 mg tablet, not a stronger shampoo.
How long before I know whether 1 mg is working?
Run six months at a minimum. A full year is fairer. Follicles answer on a slow clock. The first weeks only tell you about tolerability. Success often looks like loss stopping before obvious regrowth. Compare standardised photos in the same light, not a daily mirror hunt. If after a year the benefit is absent or a side effect matters to you, stopping or switching is reasonable. Hair held on drug will shed over the following months as DHT returns. Current regulator wording, including contraindications, is at the FDA.
Why did the 1 mg studies use a tar shampoo in the first two years?
Because the protocol wanted a clean count. All men in the pivotal vertex studies - drug and placebo - used a tar-based shampoo (Neutrogena T/Gel) for the first two years. That is a trial-hygiene detail, not a hidden extra treatment you must copy. It means both arms shared a scalp-care baseline, so the 107-hair gap is still a drug-versus-placebo gap. It does not mean 1 mg only works if you buy that shampoo. It does mean you should not credit a new wash routine for a change the tablet produced in a counted circle.
Do 1 mg reviews transfer to a man I am treating for BPH?
No. That is the mix this file exists to strike. A 26-year-old vertex trial is not a 68-year-old retention trial. Hair-line reviews tell you about counts, photos, and low-single-digit sexual adverse events at 1 mg. Prostate-line data tell you about volume, PLESS events, MTOPS combinations, and higher year-one sexual-event rates at 5 mg. You may notice hair change on 5 mg. You may notice a PSA half-cut on 1 mg. Those are crossovers, not proof the ledgers are the same. Match the milligram to the organ you are actually treating.
General education from a clinician, not personal medical advice. Bring your own history to your own prescriber.
Last Updated